of people living with HIV/AIDS, and focusing on specific,
measurable outcomes," said Dr. Jim Yong Kim, Director of the
Francois-Xavier Bagnoud Center for Health and Human Rights (FXB) at Harvard
University. "We must learn from and build on these foundations because they
represent the best chance we've ever had to build comprehensive health
systems in the poorest settings."
"It is irresponsible to get bogged down in debates on simplistic
dichotomies like prevention versus treatment or disease-specific funding
versus strong health systems. We can, and we must, do all of this, better,
for more people, and in an increasingly coherent way," added Chris Collins,
a coordinator of the project.
"The UNAIDS epidemiologic estimates released last week show that we're
getting closer to reaching the goal of treatment for all," said Shona
Schonning of the Russia research team. "The UNAIDS report shows that
prevention and treatment programming have had impact. Now its time to scale
up these programs and continue to make progress on what remains a
In the report, civil society advocates in 14 countries identify
specific problems and recommend solutions to improve AIDS drug access:
-- In Argentina, high cost and restrictions on some drugs impede access
to some second line and other medicines.
-- In Belize, human resources shortfalls, price increases and
inadequate quality assurance hamper drug delivery.
-- In Cambodia, expanded access to drug resistance and viral load
testing is needed, as is increased attention to drug quality.
-- In China, access to second-line therapy is extremely limited, new
WHO treatment guidelines on improved first-line treatment have not been
widely implemented and patents on key medicines are preventing cost-cutting
-- In the Dominican Republic, new intellectual property laws and patent
enforcement by Merck are leading to higher prices and limited acces
Page: 1 2 3 4 Related medicine technology :1
|SOURCE International Treatment Preparedness Coalition|
Copyright©2007 PR Newswire.
All rights reserved
. Trubion Announces Preliminary Analysis of Phase IIb Results With TRU-015 in Rheumatoid Arthritis2
. Oncology Drugs Development Update - Worldwide Markets and Forecasts of Approved EGFr/HEr2 Inhibitors, Treatment Costs, Pathway Analysis, Current and Expanded Clinical Indications, and Novel Agents in Development3
. New Data From Large Safety Analysis of MYCAMINE Shows Favorable Clinical Safety Profile4
. Immtech Announces Interim Analysis in Phase III African Sleeping Sickness Trial5
. Analysis Shows Vernakalant Hydrochloride Injection Increases Conversion to Normal Heart Rhythm in Acute Atrial Fibrillation Patients Treated Within 48 Hours of Onset6
. New Analysis of Study Data Shows That Asacol(R) (Mesalamine) Delivers Rapid Symptom Relief for Ulcerative Colitis Patients7
. A Sociolinguistic Analysis of In-Office Dialogue Reveals Psychiatrists and Parents Have Significantly Different Perceptions on ADHD and Psychiatric Comorbidities8
. Favrille Provides Update on Timing of Analysis from Pivotal Phase 3 Clinical Trial; Reports Third Quarter 2007 Financial Results9
. Results Of VYVANSE(TM) (lisdexamfetamine dimesylate) Effect Size Analysis Presented at Major Scientific Meeting10
. Progen Presents Additional Analysis of Data from PI-88 Phase 2 Liver Cancer Study at American Association for the Study of Liver Diseases11
. Retrospective Analysis Finds That Initiation of Insulin Glargine in Patients With Type 2 Diabetes was Associated With a Lower Incidence Rate of Myocardial Infarction as Compared With NPH Insulin